Results 211 to 220 of about 28,869 (265)

Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects

Clinical Pharmacology in Drug Development, 2018
AbstractA fixed‐dose combination of tenofovir alafenamide (TAF) and emtricitabine (FTC) is available in 2 tablet strengths in Japan (FTC/TAF 200/10 mg and FTC/TAF 200/25 mg). These are used once daily in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection.
Hiroyuki, Yamada, Takuma, Yonemura, Takanori, Nemoto, Noriko, Ninomiya, Shin, Irie   +4 more
openaire   +2 more sources

Tenofovir alafenamide

Reactions Weekly, 2022
  +4 more sources

Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study

Open Forum Infectious Diseases
Background In TANGO and SALSA, switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing a baseline regimen among adults who were treatment experienced, although few switched from bictegravir (B) / emtricitabine (F) / tenofovir ...
Charlotte-Paige Rolle, Jamie Castano, V. Nguyen, F. Hinestrosa, E. Dejesus   +4 more
semanticscholar   +1 more source

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

The Lancet HIV
BACKGROUND Doravirine and islatravir is an investigational, once-daily regimen with high antiviral potency, favourable safety and tolerability, and a low propensity for resistance.
A. Mills, Giuliano Rizzardini, M. Ramgopal, O. Osiyemi, J. Bogner, D. Hagins, R. Paredes, Jacques Reynes, Jürgen K. Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O Klopfer, Karen Eves, R. M. Plank, Todd Correll, Michelle C Fox   +15 more
semanticscholar   +1 more source

Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
BACKGROUND The ongoing, observational BICSTaR (BICtegravir Single Tablet Regimen) cohort study is evaluating real-world effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV across 14 countries over 24 ...
Yu-Ting Tseng, Chia-Jui Yang, Yeon-Sook Kim, J. Choi, Chen Seong Wong, Kuan-Yeh Lee, Jeong-a Lee, Jack Chang, R. Harrison, A. Marongiu, Sun Hee Lee, Chien-Ching Hung   +11 more
semanticscholar   +1 more source

Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.

The Lancet Gastroenterology and Hepatology
BACKGROUND Phase 3 studies in patients with chronic hepatitis B have shown tenofovir alafenamide to have non-inferior efficacy to tenofovir disoproxil fumarate, with improved renal and bone safety.
H.L. Janssen, Y. Lim, P. Lampertico, Jeong Heo, Chi-Yi Chen, Claire Fournier, T. Tsang, H. Bae, Chien-Hung Chen, C. Coffin, S. Ahn, H. Trinh, J. Flaherty, F. Abramov, Yang Zhao, Yang Liu, Audrey H. Lau, Polina German, Wan-Long Chuang, Kosh Agarwal, Edward J. Gane   +20 more
semanticscholar   +1 more source

Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.

Journal of Antimicrobial Chemotherapy
OBJECTIVES The in vivo selection of E157Q plus R263K has not been reported in patients treated with coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
L. Buzón-Martín, Carolina Navarro-San Francisco, María Fernández-Regueras, Leticia Sanchez-Gomez   +3 more
semanticscholar   +1 more source

Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

Journal of Acquired Immune Deficiency Syndromes
Supplemental Digital Content is Available in the Text. Background: Modest weight and lipid changes have been observed in cabotegravir plus rilpivirine long-acting (CAB + RPV LA) phase 3/3b studies.
Darrell H. S. Tan, A. Antinori, B. Eu, M. J. Galindo Puerto, Clifford Kinder, D. Sweet, Cornelius N. Van Dam, K. Sutton, Denise Sutherland-Phillips, Alessandro Berni, Feifan Zhang, R. Urbaityte, Bryan Baugh, W. Spreen, J. van Wyk, H. Garges, P. Patel, Rachel L Batterham, Ronald D'Amico   +18 more
semanticscholar   +1 more source

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.

Journal of Antimicrobial Chemotherapy
OBJECTIVES To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART.
Antonella d’Arminio Monforte, A. Tavelli, A. Di Biagio, L. Sarmati, G. Marchetti, F. Bai, A. Cingolani, Eugenio Quiros Roldan, C. Mussini, M. Lichtner, A. Vergori, S. Piconi, G. Orofino, F. M. Fusco, A. Bandera, S. Nozza, A. Castagna, A. Antinori   +17 more
semanticscholar   +1 more source

Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.

Clinical Infectious Diseases
BACKGROUND We evaluated associations between antepartum weight change and adverse pregnancy outcomes and between antiretroviral therapy (ART) regimens and week-50 postpartum body mass index in IMPAACT 2010.
Risa M Hoffman, S. Brummel, L. Ziemba, L. Chinula, K. McCarthy, L. Fairlie, P. Jean‐Philippe, N. Chakhtoura, Benjamin Johnston, C. Krotje, Teacler Nematadzira, Frances Nakayiwa, Victoria Ndyanabangi, S. Hanley, Gerhard B. Theron, A. Violari, E. Joao, M. C. Corrêa Júnior, C. B. Hofer, Oranich Navanukroh, L. Aurpibul, Neetal Nevrekar, Rebecca Zash, Roger Shapiro, Jeffrey S A Stringer, Judith S Currier, Paul E. Sax, S. Lockman   +27 more
semanticscholar   +1 more source